Cargando…
Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer
INTRODUCTION: Accumulating evidence suggests that both levels and activity of the estrogen receptor (ER) and the progesterone receptor (PR) are dramatically influenced by growth-factor receptor (GFR) signaling pathways, and that this crosstalk is a major determinant of both breast cancer progression...
Autores principales: | Creighton, Chad J, Fu, Xiaoyong, Hennessy, Bryan T, Casa, Angelo J, Zhang, Yiqun, Gonzalez-Angulo, Ana Maria, Lluch, Ana, Gray, Joe W, Brown, Powell H, Hilsenbeck, Susan G, Osborne, C Kent, Mills, Gordon B, Lee, Adrian V, Schiff, Rachel |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2917035/ https://www.ncbi.nlm.nih.gov/pubmed/20569503 http://dx.doi.org/10.1186/bcr2594 |
Ejemplares similares
-
Proteasome inhibition represses ERα gene expression in ER+ cells- a new link between proteasome activity and estrogen signaling in breast cancer
por: Powers, Ginny L., et al.
Publicado: (2009) -
Targeting estrogen to kill ER-positive and ER-negative breast cancer
por: Jordan, VC
Publicado: (2005) -
Estrogen Signaling in ERα-Negative Breast Cancer: ERβ and GPER
por: Girgert, Rainer, et al.
Publicado: (2019) -
The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance
por: Nardone, Agostina, et al.
Publicado: (2018) -
The Co-Expression of Estrogen Receptors ERα, ERβ, and GPER in Endometrial Cancer
por: Hojnik, Marko, et al.
Publicado: (2023)